Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: A multicentre, randomised, double-blind, parallel group, clinical study

Translational Gastroenterology and Hepatology

Volumn 3, Issue September, 2018, Pages

  Burta, Ovidiu ^a   Iacobescu, Claudia ^b   Mateescu, Radu Bogdan ^c   Nicolaie, Tudor ^d   Tiuca, Nicoleta ^d   Pop, Corina Silvia ^d  

^a UNIVERSITY OF ORADEA   (Romania)

^b Saint John Emergency Hospital   (Romania)

^c V Babes National Institute of Pathology   (Romania)

^d CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

APT036; Functional bloating; Hydrogen breath test; Simethicone

Indexed keywords

APT 036; DIGESTIVE TRACT AGENT; HEMICELLULOSE; SIMETHICONE; UNCLASSIFIED DRUG; XYLOGLUCAN;

ABDOMINAL DISTENSION; ADULT; ARTICLE; BACTERIAL OVERGROWTH; BIFIDOBACTERIUM; BIFIDOBACTERIUM BREVIS; BLOATING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; FOLLOW UP; HUMAN; HYDROGEN BREATH TEST; LACTOBACILLUS REUTERI; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 85067943206     PISSN: 2224476X     EISSN: 24151289     Source Type: Journal    
DOI: 10.21037/tgh.2018.09.11     Document Type: Article

References (25)

1. Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998;42:690-5.
2. Sandler RS, Stewart WF, Liberman JN, et al. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci 2000;45:1166-71.
3. Tuteja AK, Talley NJ, Joos SK, et al. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. Am J Gastroenterol 2008;103:1241-8.
4. Jiang X, Locke GR 3rd, Choung RS, et al. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut 2008;57:756-63.
5. Seo AY, Kim N, Oh DH. Abdominal bloating: pathophysiology and treatment. J Neurogastroenterol Motil 2013;19:433-53.
6. Iovino P, Bucci C, Tremolaterra F, et al. Bloating and functional gastro-intestinal disorders: where are we and where are we going? World J Gastroenterol 2014;20:14407-19.
7. Foley A, Burgell R, Barrett JS, et al. Management strategies for abdominal bloating and distension. Gastroenterol Hepatol (N Y) 2014;10:561-71.
8. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition. Boca Raton, FL, USA: CRC Press; 2011.
9. MedicineNet.com. Simethicone. Available online: https://www.medicinenet.com/simethicone/article.htm [Accessed 16 March 2018].
10. Meier R, Steuerwald M. Review of the therapeutic use of simethicone in gastroenterology. Schweizerische Zeitschrift fur GanzheitsMedizin 2007;19:380-7.
11. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, et al. Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex 2012;77:82-90.
12. Piqué N, Gómez-Guillén MDC, Montero MP. Xyloglucan, a plant polymer with barrier protective properties over the mucous membranes: an overview. Int J Mol Sci 2018;19:E673.
13. Noventure. Aprotecol® package insert. Available online: http://noventure.com/aprotecolr-drops (2017 accessed 13 March 2018).
14. Erdogan A, Rao SS, Gulley D, et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 2015;27:481-9.
15. König J, Wells J, Cani PD, et al. Human intestinal barrier function in health and disease. Clin Transl Gastroenterol 2016;7:e196.
16. Brune K, Frank J, Schwingshackl A, et al. Pulmonary epithelial barrier function: some new players and mechanisms. Am J Physiol Lung Cell Mol Physiol 2015;308:L731-45.
17. Gon Y, Hashimoto S. Role of airway epithelial barrier dysfunction in pathogenesis of asthma. Allergol Int 2018;67:12-7.
18. Pleșea Condratovici C, Bacarea V, Piqué N. Xyloglucan for the treatment of acute gastroenteritis in children: results of a randomized, controlled, clinical trial. Gastroenterol Res Pract 2016;2016:6874207.
19. Gnessi L, Bacarea V, Marusteri M, et al. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial. BMC Gastroenterol 2015;15:153.
20. Allegrini A, Pavone D, Carluccio F. A randomized controlled trial comparing a xyloglucan-based nasal spray with saline in adults with symptoms of rhinosinusitis. Curr Med Res Opin 2018;34:377-85.
21. Rolando M, Valente C. Establishing the tolerability and performance of tamarind seed polysaccharide (TSP) in treating dry eye syndrome: results of a clinical study. BMC Ophthalmol 2007;7:5.
22. Alexea O, Bacarea V, Piqué N. The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial. United European Gastroenterol J 2016;4:455-65.
23. García-Larrosa A, Alexe O. Efficacy and safety of a medical device versus placebo in the early treatment of patients with symptoms of urinary tract infection: a randomized controlled trial. Clin Microbiol 2016;5:233.
24. Salvatorelli N, García-Larrosa A, Allegrini A, et al. A new approach to the treatment of uncomplicated cystitis: results of a randomized placebo-controlled clinical trial. Urol Int 2016;97:347-51.
25. Vandenplas Y, Bacarea A, Marusteri M, et al. Efficacy and safety of APT198K for the treatment of infantile colic: a pilot study. J Comp Eff Res 2017;6:137-44.